LXEO — Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic ca...

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Industry

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Sector

Healthcare

Exchange

NASD

First trade date

2023-11-03

The interactive platform loads with JavaScript. Research tools are for informational purposes.